PathAI and ConcertAI partner to advance real-world evidence by uniquely linking pathology and real-world clinical datasets
The strategic partnership between PathAI and ConcertAI creates first-in-class quantitative histopathology and curated clinical real-world data solution to enable novel insights for researchers.
In late April 2023, PathAI and ConcertAI announced a strategic new partnership that will combine PathAI’s proprietary PathExplore™ tumor microenvironment panel with ConcertAI’s Patient360™ and RWD360™ products to launch a first-in-class quantitative histopathology and curated clinical real-world data (RWD) solution. The collaboration, initially focusing on bladder cancer, colorectal cancer, prostate cancer, and melanoma, opens the realms of novel insights for researchers in biopharma, including translational research and real-world data teams.
“Real-world data products include clinical and outcomes data, but are missing a critical component that links these, namely pathology, which has historically been non-standardized or with limited quantification,” explained Andy Beck, CEO and co-founder of PathAI, a global leader in artificial intelligence (AI) powered quantitative histopathology. “Our collaboration with ConcertAI will offer access to a uniquely linked quantitative pathology dataset, allowing researchers to explore hypotheses far beyond the scope of small, controlled datasets, such as identifying and analyzing novel histological biomarkers correlated with patient treatment and outcomes.”
PathAI’s PathExplore extracts quantitative measures of tumor microenvironment, known as human interpretable features (HIFs), from whole histology slide images of real-world hematoxylin- and eosin-stained samples from PathAI’s pathology laboratory. Through the partnership with ConcertAI, these data are linked to Patient360’s abstracted clinical electronic medical records (EMR), medical claims, and social determinants of health data. Linking similarly into RWD360 provides scaled insights from structured EMR data, medical claims, and social determinants of health for large populations.
“Analysis of tumor microenvironment characteristics is critical to understanding why certain patients respond to a specific therapy and others do not. It further allows the definition of clinical strategies that might increase the numbers of patients benefiting from current medicines and improve the effectiveness of new ones,” said Jeff Elton, CEO of ConcertAI, a leader in AI software-as-a-service technology and real-world evidence solutions for life sciences and healthcare. “With PathAI we are creating the first large scale clinical datasets linking pathology HIFs with EMR-derived clinical data, greatly enhancing the armamentarium of the translational and clinical development research communities.
